Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

[1]  L. Salmena,et al.  Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers , 2016, Oncotarget.

[2]  J. Visvader,et al.  RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers , 2016, Nature Medicine.

[3]  Molin Wang,et al.  Statistical methods for studying disease subtype heterogeneity , 2016, Statistics in medicine.

[4]  G. Ning,et al.  Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study , 2015, BMC Endocrine Disorders.

[5]  N. Sharma-Walia,et al.  Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis , 2015, BMC Cancer.

[6]  T. Griffith,et al.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond. , 2015, Pharmacology & therapeutics.

[7]  R. Kaaks,et al.  Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg. , 2015, Journal of the National Cancer Institute.

[8]  I. Jacobs,et al.  Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers , 2015, EBioMedicine.

[9]  S. Chung,et al.  Osteoprotegerin in breast cancer: beyond bone remodeling , 2015, Molecular Cancer.

[10]  A. Lawrie,et al.  Osteoprotegerin in Cardiometabolic Disorders , 2015, International journal of endocrinology.

[11]  J. Hansen,et al.  Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study , 2015, European Journal of Epidemiology.

[12]  H. Park,et al.  Expression of receptor activator of nuclear factor kappa‐B as a poor prognostic marker in breast cancer , 2014, Journal of surgical oncology.

[13]  Tanja Fehm,et al.  OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer , 2014, Molecular oncology.

[14]  Seema A. Khan,et al.  RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase , 2014, Breast Cancer Research and Treatment.

[15]  S. Rosso,et al.  Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  D. Geerts,et al.  Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis , 2014, Cancer Medicine.

[17]  I. Gram,et al.  Insulin‐like growth factor I and risk of breast cancer by age and hormone receptor status—A prospective study within the EPIC cohort , 2014, International journal of cancer.

[18]  F. Clavel-Chapelon,et al.  Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—Results from the EPIC cohort , 2014, International journal of cancer.

[19]  R. Schwab,et al.  Reproductive risk factors and breast cancer subtypes: a review of the literature , 2014, Breast Cancer Research and Treatment.

[20]  R. Kovatcheva,et al.  Age and Menopausal Status Affect Osteoprotegerin and Osteocalcin Levels in Women Differently, Irrespective of Thyroid Function , 2014, Clinical medicine insights. Endocrinology and diabetes.

[21]  A. Nogalski,et al.  Influence of hormone replacement therapy on osteoprotegerin and receptor activator of nuclear factor kappa-B ligand concentrations in menopausal women. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[22]  D. Branstetter,et al.  Progestin effects on cell proliferation pathways in the postmenopausal mammary gland , 2013, Breast Cancer Research.

[23]  Wassim Raffoul,et al.  Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast , 2013, Science Translational Medicine.

[24]  A. Farooqi,et al.  Breast Cancer Proteome Takes More Than Two to Tango on TRAIL: Beat Them at Their Own Game , 2012, The Journal of Membrane Biology.

[25]  J. Aubin,et al.  Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. , 2011, Cancer research.

[26]  R. E. James,et al.  Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study , 2011, Cancer Prevention Research.

[27]  C. Porta,et al.  Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients , 2011, PloS one.

[28]  J. Hansen,et al.  Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study , 2011, Journal of thrombosis and haemostasis : JTH.

[29]  A. Trouvin,et al.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss , 2010, Clinical interventions in aging.

[30]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[31]  M. Widschwendter,et al.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.

[32]  J. Li,et al.  Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  C. Clarke,et al.  Progesterone induces adult mammary stem cell expansion , 2010, Nature.

[34]  N. Ben-Jonathan,et al.  Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. , 2010, Endocrine-related cancer.

[35]  C. Brisken,et al.  Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland , 2010, Proceedings of the National Academy of Sciences.

[36]  J. Manson,et al.  Breast cancer after use of estrogen plus progestin in postmenopausal women. , 2009, The New England journal of medicine.

[37]  Y. Onoe,et al.  Variations in Circulating Osteoprotegerin and Soluble RANKL during Diurnal and Menstrual Cycles in Young Women , 2009, Hormone Research in Paediatrics.

[38]  D. Kiel,et al.  Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. , 2008, The Journal of clinical endocrinology and metabolism.

[39]  P. Meltzer,et al.  TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype , 2008, Breast Cancer Research and Treatment.

[40]  G. Emons,et al.  Expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[41]  M. Losa,et al.  Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells. , 2007, The Journal of endocrinology.

[42]  S. Cross,et al.  Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables , 2006, Journal of Clinical Pathology.

[43]  S. Cross,et al.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours , 2006, Journal of Clinical Pathology.

[44]  S. Cross,et al.  Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival? , 2005, Breast Cancer Research and Treatment.

[45]  Hyun Ah Choi,et al.  The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone , 2005, Clinical endocrinology.

[46]  P. Olesen,et al.  Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α , 2005, Diabetologia.

[47]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[48]  J. Holly,et al.  Prolactin acts as a potent survival factor for human breast cancer cell lines , 2004, British Journal of Cancer.

[49]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[50]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[51]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[52]  F. Hamdy,et al.  The survival effect of prolactin on PC3 prostate cancer cells. , 2003, European urology.

[53]  R. Eastell,et al.  Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. , 2002, The Journal of clinical endocrinology and metabolism.

[54]  S. Iturria,et al.  Differential Gene Expression of TGF-β Family Members and Osteopontin in Breast Tumor Tissue: Analysis by Real-Time Quantitative PCR , 2002, Breast Cancer Research and Treatment.

[55]  L. Melton,et al.  Correlates of Osteoprotegerin Levels in Women and Men , 2002, Osteoporosis International.

[56]  William Maloney,et al.  Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.

[57]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[58]  E. Ogata,et al.  Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. , 2000, Biochemical and biophysical research communications.

[59]  P. Young,et al.  Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. , 1997, Gene.

[60]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[61]  E. Riboli,et al.  Nutrition and cancer: background and rationale of the European Prospective Investigation into Cancer and Nutrition (EPIC). , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[63]  B. Rosner.  Percentage Points for a Generalized ESD Many-Outlier Procedure , 1983 .

[64]  M. Mason,et al.  Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. , 2013, Anticancer research.

[65]  T. Bevers,et al.  Breast cancer risk in relation to the interval between menopause and starting hormone therapy: Beral V, for the Million Women Study Collaborators (Univ of Oxford, UK; Et al) J Natl Cancer Inst 103:296-305, 2011 , 2011 .

[66]  J. Pumphrey,et al.  The TRAIL to targeted therapy of breast cancer. , 2009, Advances in cancer research.

[67]  P. Brown,et al.  Decreased TGFβ signaling and increased COX2 expression in high risk women with increased mammographic breast density , 2009, Breast Cancer Research and Treatment.

[68]  M. Hansen,et al.  Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  S. Iturria,et al.  Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. , 2002, Breast cancer research and treatment.

[70]  T. Martin,et al.  Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .